Test Code 4366SP

Test Name Teriflunomide (Therapeutic Drug Monitoring), Serum/Plasma

Purpose
This test is designed for the therapeutic drug monitoring of teriflunomide levels to ensure adequate dosage. The minimum reporting limit of this assay is 500 ng/mL. THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE TERIFLUNOMIDE
Method(s)
High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)
Suggested CPT Code(s)
80375
New York State Approval Status

Approved

Turnaround Time

7 days

Test Includes
1 Teriflunomide Aubagio® High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) ng/mL 500 Immunomodulator

Compliance Statement
This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.
Specimen Type
Serum or Plasma
Requested Volume
1 mL
Minimum Volume
0.2 mL
Special Handling
Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Specimen Container
Plastic container (preservative-free)

Additional Collection Instructions

Transport Temperature
Refrigerated
Light Protection
Not Required
Rejection Criteria
Polymer gel separation tube (SST or PST).

Rejection criteria pertain to clinical specimen submissions only.

Stability
Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)
1 Teriflunomide Aubagio® High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) ng/mL 500 Immunomodulator

Interface Map

LOINC® Information

The CPT Codes provided in this document are based on AMA Guidelines and are for informational purposes only. NMS Labs Does not assume responsibility for billing errors due to Reliance on the CPT Codes listed in this document.

*The information contained in this document represents database configurations, as they will appear on the effective date listed above.